The present data support the contention IL-6 signaling is upstream of a maladaptive cytokine and chemokine cascade capable of suppressing anti-tumor effector responses at the level of effector T cells and macrophages and promoting EMT and aggressive tumor behavior. The gene discussed is IL6; the disease is neoplasm.